Evidence map›Paper›PMID 36387052›Full record

ArticlePatient preference and adherence2022

Utilization of Hydroxyurea Among Patients Diagnosed with Sickle Cell Disease in Jazan, Saudi Arabia.

Gassem A Gohal, Ibrahim M Gosadi, Basheer Ahmed Cittana Iqbal, Yahya H Ghazwani, Amal M Daghriri, Ahmad A Shugairi, Khaled A Daghriri, Atyaf J Zurayyir, Abdulrhman A Nemri, Monera A Abdulhaq

Open access · goldAbstract read
In one paragraph

Article in Patient preference and adherence, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 6 citations in OpenAlex.

  1. Therapeutic Role of Hydroxyurea in Paediatric Hydroxyurea Pertussis:Sultan Qaboos University medical journal · 2025
    Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Gassem A GohalDepartment of Pediatrics, Faculty of Medicine, Jazan University, Jazan, Saudi Arabia.
Ibrahim M GosadiDepartment of Family and Community Medicine, Faculty of Medicine, Jazan University, Jazan, Saudi Arabia.ORCID 0000-0002-1275-3953
Basheer Ahmed Cittana IqbalDepartment of Pediatric Hematology and Oncology, Prince Mohammed Bin Nasser Hospital, Jazan, Saudi Arabia.
Yahya H GhazwaniDepartment of Pediatric Hematology and Oncology, Prince Mohammed Bin Nasser Hospital, Jazan, Saudi Arabia.
Amal M DaghririDepartment of Pediatric Hematology and Oncology, Prince Mohammed Bin Nasser Hospital, Jazan, Saudi Arabia.
Ahmad A ShugairiDepartment of Adult Hematology and Oncology, Prince Mohammed Bin Nasser Hospital, Jazan, Saudi Arabia.
Khaled A DaghririDepartment of Internal Medicine, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
Atyaf J ZurayyirDepartment of Obstetrics and Gynecology, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
Abdulrhman A NemriDepartment of General Surgery, Security Force Hospital, Riyadh, Saudi Arabia.
Monera A AbdulhaqFaculty of Medicine, Jazan University, Jazan, Saudi Arabia.
Prince Mohammed bin Abdulaziz Hospital · SAJazan University · SAKing Abdulaziz Medical City · SARiyadh Armed Forces Hospital · SASecurity Forces Hospital · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The early diagnosis of sickle cell disease (SCD) patients and getting appropriate treatment are crucial for improving clinical outcomes. This study aims to assess the use of hydroxyurea among patients diagnosed with SCD and assess factors influencing the attitude toward the medication and the reasons for discontinuation. Methods: This study was a cross-sectional investigation targeting parents or caregivers of children diagnosed with SCD in the Jazan region of Saudi Arabia. Data were collected from tertiary healthcare hospitals via a self-administered questionnaire. The questionnaire was composed of sections measuring the participants' demographics, the number of children diagnosed with SCD, the use of hydroxyurea, and the parents' beliefs about hydroxyurea. Results: There were 301 parents or caregivers recruited. The majority of the recruited participants were mothers (54.5%), and nearly half of the sample were older than 35. More than 80% of the participants declare that one or more of their children are receiving hydroxyurea to manage SCD. The majority of participants declared that using hydroxyurea reduced the frequency of body pain episodes, emergency department visits, and hospital admissions. Participants' major concern about the use of hydroxyurea was related to the fear of weakening their immunity (29.5%) and hydroxyurea's perceived effect on fertility (16.8%). Furthermore, 52 (18%) of the participants declared that the use of hydroxyurea to manage the disease was stopped; the main reasons for stopping was their belief that hydroxyurea had side effects and its impact on weakening of their immune system. Conclusion: The findings indicate the importance of increasing the role of clinicians in educating patients and caregivers about the use of hydroxyurea and its benefits.

Indexed as

hydroxyureaJazanSaudi Arabiasickle cell disease

Identifiers

PMID36387052
PMCPMC9653045
OpenAlexW4308431112

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.